LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Deschisă

Sector Sănătate

487.75 0.46

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

483.79

Maxim

488.76

Indicatori cheie
By Trading Economics
Venit	-4.7B -3.6B
Vânzări	-40M 2.7B
P/E Medie Sector	30.09 103.001
EPS	-12.83
Marjă de profit	-135.608
Angajați	5,400
EBITDA	263M 1.3B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+5.26 upside

Dividende
By Dow Jones
Următoarele câștiguri	4 nov. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	128B
Deschiderea anterioară	487.29
Închiderea anterioară	487.75

Sentimentul știrilor

By Acuity

17%

83%

18 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

478.57 / 492.29 Suport & Rezistență

Vertex Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 aug. 2024, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

6 mai 2024, 20:37 UTC

Câștiguri

Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug

10 apr. 2024, 22:48 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

10 apr. 2024, 21:40 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.

10 apr. 2024, 21:24 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 apr. 2024, 20:30 UTC

Top știri

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion

1 aug. 2024, 20:30 UTC

Câștiguri

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1 aug. 2024, 20:03 UTC

Câștiguri

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1 aug. 2024, 20:02 UTC

Câștiguri

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1 aug. 2024, 20:02 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

27 iun. 2024, 20:15 UTC

Achiziții, Fuziuni, Preluări

Vertex Also Sees About $200M of Transaction-Related Compensation Expense Associated With Acceleration of Unvested Awards Pursuant to Alpine Equity Incentive Plans

27 iun. 2024, 20:14 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals Expects to Record About $4.4B One-Time Acquired In-Process R&D Expense Related to May Purchase of Alpine Immune Sciences

6 mai 2024, 21:00 UTC

Câștiguri

Vertex Beats Quarterly Forecasts, But Its Pipeline Remains Key -- IBD

6 mai 2024, 20:15 UTC

Câștiguri

Vertex Beats First-Quarter Expectations, But Shares Stay Flat On Reiterated Outlook -- IBD

6 mai 2024, 20:03 UTC

Câștiguri

Vertex Pharmaceuticals: Reiterated Full Yr 2024 Fincl Guidance, Including Pdt Rev Guidance of $10.55B to $10.75 B >VRTX

6 mai 2024, 20:03 UTC

Câștiguri

Vertex Pharmaceuticals 1Q Rev $2.69B >VRTX

6 mai 2024, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 1Q Net $1.1B >VRTX

6 mai 2024, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 1Q Adj EPS $4.76 >VRTX

6 mai 2024, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 1Q EPS $4.21 >VRTX

23 apr. 2024, 18:54 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk

11 apr. 2024, 20:18 UTC

Achiziții, Fuziuni, Preluări

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It -- IBD

11 apr. 2024, 16:54 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Alpine Deal Seen Giving Vertex New Expertise -- Market Talk

11 apr. 2024, 14:46 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

11 apr. 2024, 13:47 UTC

Acțiuni populare

Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands -- WSJ

10 apr. 2024, 21:47 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 apr. 2024, 21:09 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B -- Update

10 apr. 2024, 20:46 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal -- IBD

10 apr. 2024, 20:15 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9B

10 apr. 2024, 20:04 UTC

Achiziții, Fuziuni, Preluări

Alpine Immune Sciences: Vertex Will Acquire Alpine for $65 Per Shr or Approximately $4.9B in Cash, Transaction Approved by Both Boards of Directors, Anticipated to Close in 2Q >ALPN

10 apr. 2024, 20:03 UTC

Achiziții, Fuziuni, Preluări

Vertex Subsidiary Will Commence Cash Tender Offer to Purchase All Alpine Common Stk >VRTX

Comparație

Modificare preț

Vertex Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

5.26% sus

Prognoză pe 12 luni

Medie 510.9 USD 5.26%

Maxim 600 USD

Minim 325 USD

În baza a 23 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVertex Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

23 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 23 analiști care au acordat evaluări ale acțiunilor Vertex Pharmaceuticals Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

478.57 / 492.29Suport & Rezistență

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

18 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.